Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL4744382

O=S(=O)(O)C(F)(F)F.c1cn[nH]c1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrazole SCHEMBL28395893 0.85 TSHR (0.38)
Sulfuric Acid SCHEMBL30034939 0.84 CA5A (0.32)
Sulfuric Acid SCHEMBL624266 0.84 CA5A (0.32)
Sulfuric Acid SCHEMBL28166939 0.82 CA5A (0.30)
Sulfuric Acid SCHEMBL28329764 0.82 CA5A (0.30)
Sulfuric Acid SCHEMBL29131540 0.82 CA5A (0.30)
Sulfamate SCHEMBL28005026 0.80 CA1 (0.38)
Trifluoroacetic Acid SCHEMBL2074324 0.77 CES1 (0.31)
Pyrazole SCHEMBL19615038 0.77
Sulfamide SCHEMBL28146364 0.75 CA1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200317976-A1 NOVEL PHASE CHANGE MATERIAL AND METHODS OF USE MONASH UNIVERSITY (AU) 2020-10-08 US claimed
EP-3458539-A1 NOVEL PHASE CHANGE MATERIAL AND METHODS OF USE Monash University (AU) 2019-03-27 EP claimed
WO-2017197438-A1 NOVEL PHASE CHANGE MATERIAL AND METHODS OF USE MONASH UNIVERSITY (AU) 2017-11-23 WO claimed
CN-115996924-B Substituted pyrazolyl compounds and methods of use thereof 诺华医药股份公司 2025-03-07 CN disclosed
US-20240383885-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose MAKSCIENTIFIC, LLC 2024-11-21 US disclosed
CN-108368040-B Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections 默沙东有限责任公司 2024-08-23 CN disclosed
CN-111201021-B Chroman monocyclic beta-lactams for the treatment of bacterial infections 默沙东有限责任公司 2024-08-23 CN disclosed
CN-118496221-A Chroman monocyclic beta-lactams for the treatment of bacterial infections 默沙东有限责任公司 2024-08-16 CN disclosed
US-12054480-B2 Compounds for treating cannabinoid toxicity and acute cannabinoid overdose MAKSCIENTIFIC, LLC (US) 2024-08-06 US disclosed
US-11939325-B2 Process for making biologically active compounds and intermediates thereof MAKSCIENTIFIC, LLC (US) 2024-03-26 US disclosed
CN-111171014-B Monocyclolactam compounds and uses thereof 南京圣和药业股份有限公司 2023-11-07 CN disclosed
CN-1882590-B Fused heterocyclic compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV 2014-03-05 CN disclosed
CN-101318961-B Fused heterocyclic compound JANSSEN PHARMACEUTICA NV 2012-11-28 CN disclosed
CN-101318961-A Fused heterocyclic compound JANSSEN PHARMACEUTICA NV (BE) 2008-12-10 CN disclosed
CN-101318962-A Fused heterocyclic compound JANSSEN PHARMACEUTICA NV (BE) 2008-12-10 CN disclosed
WO-2008101860-A1 NOVEL PROCESS FOR THE PREPARATION OF 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-N-(PIPERIDIN-1-YL)PYRAZOLE-3-CARBOXAMIDE SANDOZ AG (CH) 2008-08-28 WO disclosed
US-7358371-B2 Process for the preparation of 1,5—carboxylic acid derivatives SANOFI-AVENTIS (FR) 2008-04-15 US disclosed
US-20070099978-A1 Process for the preparation of 1,5 - carboxylic acid derivatives SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
CN-1934089-A Process for preparing 1, 5-diphenylpyrazole-carboxylic acid derivatives SANOFI AVENTIS (FR) 2007-03-21 CN disclosed
CN-1882590-A Fused heterocyclic compounds as serotonin receptor modulators JOHNSON & JOHNSON (BE) 2006-12-20 CN disclosed